Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Xegafri (rociletinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Clovis

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	rociletinib Sensitive: B - Late Trials rociletinib Sensitive : B	rociletinib Sensitive: B - Late Trials rociletinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	rociletinib Resistant: C3 – Early Trials rociletinib Resistant : C3	rociletinib Resistant: C3 – Early Trials rociletinib Resistant : C3
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	rociletinib Sensitive: D – Preclinical rociletinib Sensitive : D	rociletinib Sensitive: D – Preclinical rociletinib Sensitive : D